Eli Lilly (LLY): FY24 Q3 earnings call, Oct 30, 2024
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2024 earnings call (FY24 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
28 matches for “Zepbound”; 5 quoted, at least 25 words apart.
…New product revenue grew by over $3 billion led by Mounjaro and Zepbound. U.S. demand for Mounjaro and Zepbound has been strong and continues to…
…the wholesale channel and LillyDirect Pharmacy Solutions. The launch of a single-dose Zepbound vials in the U.S. exclusively through LillyDirect's self-pay channel further expanded supply…
…revenue from the olanzapine portfolio and was primarily driven by Mounjaro and Zepbound. Revenue from our non-incretin portfolio grew 17% after excluding the impact of…
…revenue growth. U.S. revenue increased 46% with volume growing 35% driven by Zepbound Mounjaro and partially offset by declines in Trulicity. Realized prices increased 11%…
…combinations. We estimate this inventory decrease impacted Q3 sales of Mounjaro and Zepbound by mid-single digits as a percentage of aggregate used sales of these…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2024-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2024-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP